Hey wombat777 [link]  First of all I wishing you a speedy recovery. Get better soon, the world needs your positive energy!  Secondly from the bottom o

General Discussion

"Technical Analysis from A to Z" by Steven B. Achelis.     Close to 400 pages covering every important Technical Indicator. It is a must read for anyo

A comprehensive guide to Technical Indicators.

Been a while now since the last post on AX1 but what a difference has occurred. An absolutely stellar run since the end of the Covid era.     As a cha

Accent Group

Google "Mitozantrone". It's cardiotoxic. Lederle chose the wrong one.

The PRV date keeps getting extended.  Which US political party wants to be blamed for not helping sick kids?     This reminds me of statutory limits o

we know that mitozantrone was chosen over Bisantrene And Molecule and function seems similar.    @Raceoncology is it known whether Mitozantrone inhibi

Updating WKT after a bit of a rocky road for the company, a cap. raising and financial moves.     Since settling into a new share price envelope WKT h

Chart thread

https://www.cancer.gov/news-events/cancer-currents-blog/2023/childhood-cancer-dexrazoxane-protects-heart-doxorubicin [link]     Speaking of paediatric

What do people think about the possibly of CBA Commonwealth Bank continue buying of Credit Corp shares and doing a full TAKEOVER of CCP?  It seems to 

TAKEOVER chances? CBA Commonwealth Bank recently bought a huge amount of Credit Corp CCP shares.

Id say he's mates with Dominissini and Nagler as well. So he'd be well informed of the goings on behind the scenes. 

I wonder if Dr Ikaobishvili has reviewed Dr Sverdlov’s paper that is planned to be submitted to a high impact scientific journal given he is on the ed

   The standout part for me how important this trial is and how many important people in the medical field are watching and reacting to these tweets b

Zaza Iakobishvili, MD, PhD is a director of Community Cardiology Department in Tel Aviv district of Clalit Health Services since 2018. Dr. Iakobishvil

Good find @Teeth [link]     https://ic-os.org/zaza-iakobishvili/ [link] 

@RaceOncology [link] is there any update you can share on the European rollout of the EMD AML trial?

RAC Media Coverage

We are pushing this trial forward as fast as is possible. Fortunately or unfortunately (depending on your view) there are enormous hurdles in front of

Thanks Dr.T. Any reason we couldn’t have started this observational leg sooner? I am just trying to understand the sequencing and dependencies. 

The answer is you don't need to know the mechanism of action for approval, but it will make your life much easier if your do. I am confident that we w

Industry news - New thread

Nothing to report at this stage. Everything is progressing as expected.

Ann: Ethics submission to commence cardioprotection trial

They can run in parallel. We don't need the data from the observational trials to start the Phase 1 trial, we only need it at the end to compare with 

If I'm understanding these announcement correctly, the observational study is planned to run through 2023, and but the clinical study isn't dependent 

The observational stage is just that - observational. It's not influencing Zantrene dosing or proposing to change the AC SOC treatment or anything els

Uneducated me, understand that the trials will run parallel. The results at the end will just be compared for efficacy. 

I was going to post something similar after listening to that interview.      The observational stage of the trial provides the data/evidence base for

Dr. T, Damian mentions that the observational study will go on for 12 months. Will the Zantrene treatment start after that? Could this have started so

Broad-MIT Seminars in Chemical Biology : Chuan He (2023)      

Another excellent tweet by “Andrew”.  😂 

@RaceOncology [link] have you any update on how the supply of the new formulation is going? / is there anything to suggest that the original timeline 

@IndexInvestor - FYI it’s Iron depletion using HCI 😁     I assume the FDA like to know the MOA if known to understand and ensure no adverse side effe

Yes, it would be surprising if someone had already found the theoretical MOA of a hypothetical cardioprotective drug synergistic with cancer treatment

Agree but  Cardio Protection (CP) is unique. I am guessing that there is no research paper out there that has documented the MOA for CP and cancer eff

Imagine the market reaction if FDA rejected based on not understanding MOA, linking it to possible safety concerns and rejecting a submission.   Even 

The FDA may have stronger requirements for knowing the MOA of drugs which don't act on the brain.

This is true but adding the MOA to our IP will be worth a few more bob.

I attended the Neuren investor webinar today out of curiosity and I asked a question which was triggered by their pack yesterday.  My question: Does t

Refer the March 2021 strategic update about the breast cancer trial, but may have changed given cardio protect.

   Thanks. Will there be a separate design announced for the phase 2b?

An observational trial is not really open label as there is nothing that even in principle could be concealed. The aim of this trial is to get high qu

Maybe because a pure open label trial doesn't have a control arm, either placebo or synthetic??     Anyway, all patients in the intervention phase wil

Thanks but why can’t I find the words ”open label” anywhere in the Ann?     https://newswire.iguana2.com/af5f4d73c1a54a33/announcements/rac.asx/2A1419

It's open label.  See the announcement of 9 December 2022.  The observation phase becomes a synthetic control arm for the intervention phase.  Everyon

Dr.T:     What next after cardio protection (CP) from Breast cancer trials? Do we need more CP trials though we know Zantrene is cardio protective?   

How will we be able to disentangle Zantrene's effect on FTO with any unexpected effect of the AC treatment on FTO? Will there be another control group

Garymeme is always there to say something silly whenever we release an announcement.     These announcements are made when the contracts are signed. T

We won't be collecting anything about FTO in this first trial as Zantrene is not being used, but we will in later trials.

We can reveal everyones holdings if we wish, the only rules around this is we must reveal the T20 in the annual report, but we can and do reveal holdi

Good question, let's see what Dr T says.  The AC treatment might have a small unintended effect on FTO, and knowing the direction and size would be he

RAC is always there with a meme announcement during or after a big fall of it's Share price.     If you got any brains...... ..... ....... ....... 

Dr.T -  can i please confirm if any FTO biomarkers will be collected pre and post treatment though FTO isn’t believed to be the MOA for cardio protect

The ASX market is hopeless at valuing biotechs.   Full stop.  There's nothing that any one biotech company can do about it.  Please try to relax and e

No need to wait a few weeks.  Economics 101 is that a long term seller widely known to have only a small supply remaining has already triggered a FOMO

AFAIK, RAC's announced collaboration with University of Texas MD Anderson Cancer Center is about AML, not about cardiooncology.  That's not to say the

Pillar 1 - Zantrene / AML & Cardioprotection

@BruceKoala [link]     Thanks Bruce. It's just a big worry to myself and others that started investing at the top. Averaging down along the way but st

The dilemma @ask79 is that while we know just one seller, WG has accounted for 12-15% of  all seller orders for a very long time now, we don’t know ho

Seem to be a lot of cardioncology conferences happening in person at the moment.  Saw some Japanese tweets about Symposium in Japan & couldn’t help bu

@Raceoncology I understand IND applications are very onerous 2000+ pages.       1. How much work can be reused for IND submissions for different indic

what prevents one shareholder who has looked at the registry from advising another?  providing It doesn’t contravene s.177 corporations act then shoul

Who cares Index…. Its good intel. We could all go into the automatic office and have a sneak peak…

How is it that a company is allowed to reveal individual holdings not in the T20 and not held by a current Director?

At least it reduces not only the daily selling, but especially selling into Anns, so the sp can start to appreciate on a great Ann, instead of just ho

If BG exits and his 15% a day selling stops will the other 85% of the days selling stop also? 

if bg increase his selling, i wonder if he may use his last 200k to damage the sp.

Do you think you could update us interested holders here on the forums once our former chairman has sold out completely by your records?  Thanks 😁

Not a huge amount I can say. Most of the buying and selling is coming out of nominee accounts. I can say that our former chairman has picked up his se

I guess we all have different ideas on Dr T’s role and priorities, but if he’s working over the weekend I’d prefer him to be thinking up value creatin

Spoke to a friend in Big Pharma who runs US and EUR trials and develops CDx.  Despite their basically unlimited resources the EMA changes in Europe ar

Greetings Dr T  @RaceOncology [link]     I know you are pedal to the metal, however with the increased selling (and buying volume) this week, are you 

Brad Loncar discusses Biotech Stocks     https://twitter.com/TDANetwork/status/1633849124356341760 [link]      

RESULTS  High expression of FTO and an increased capacity for migration were observed in high glucose-treated primary VSMC. Moreover, inhibiting FTO a

FTO Related Research

That’s probably ppl searching CS1 counterstrike1 😋

Here is a google trends report showing CS1 is searched much more than Zantrene or Bisantrene 😉     [image]

The whole website is undergoing a complete overhaul - the difficulty has been getting the time to work on it.

Hey Dr T,  May I suggest you set up RAC's website with lots of keywords and references to "CS1" making it pretty clear CS1 and Zantrene (....and Bisan

It is an add on to existing anthracycline use.

There is no country in the world where the competition for AML patients is not intense.     Cardioprotection has no direct competitor and the anthracy

Is cardio protection tied to a cancer trial than standalone?

Perhaps we need to go and run trial in a country where there is less competition. E.g. Asian country, for AML.  Also, Europe can’t come soon enough.  

There are 32 clinical trials recruiting in Australia for AML. The competition for AML patients is intense.      https://clinicaltrials.gov/ct2/results

Interesting… in this new research report on Leukaemia market size and competition we are mentioned as a new entrant and on the same list as Pfizer, BM

Charts & Price Action

Haven’t checked but I doubt EMD AML is specifically called out as exclusion criteria ( it might just be captured in a general criteria about patient c

I understand that AuStralia has circa 900 cases of AML per annum.  If EMD are 20% this is 180 and if less than 20% clinicians Adopt a PET scan this is

Was that you @Maddy that dropped all those 2G parcels today. Are you going to buy back in at one dollar ninety? 

I respect your honesty in replying to us mate. But the trial in Newcastle is a fail with no recruits after 12months. How are you going to make up for 

Test run of companion diagnostic in Vitro should speed it up.  We already know companion diagnostic has progressed to in vivo so in vitro beta version

"Race is an iceberg" - Price Sensitive 😎😁

Shouldnt a good company like Race start bucking the trend by now? Has Danny or DCB attracted anyone to buy? Seems like we only have selling. Big pump 

I’m patiently waiting for the day the Race iceberg has revealed itself & melted down to an Ice Cube 🤣🤙

Race like nearly every company in the biotech sector had a massive run up over the covid period. We have fallen back less than many other companies an

I know none of my fellow directors are as interested in investing as myself. I would go so far as to say none are serious investors beyond the usual super investing. I am the only director that came to Race via an investment in the company - everyone else was invited and appointed to fill a gap in the board skills matrix. There is nothing wrong with this, but as shareholders you can't expect non-investor directors to behave like an investor director such as myself.     I only joined the Race boa

Ann: Danny Sharp appointed Independent Non-Executive Director

Everyone I can’t announce price sensitive news here. I know you all want to know what is going on at Race, but until it is announced via the ASX I can’t talk about it. I can say that I have never been busier (if that is possible) and that there will be a lot of news in 2023.

After talking to a shareholder I thought I should add to this rather short statement as it might have been confusing. We aren't planning on taking Zantrene through to market ourselves or even thinking about trying to sell the drug directly to patients - Zantrene has far too much potential for us to even consider this. Zantrene is a drug where only the largest pharma companies will extract the full commercial potential from it. Our intention remains to prove out the drug to Phase 2 and sell/licen

Ann: (!) Race Appoints Damian Clarke-Bruce as CEO & Managing Director

Exactly right. The appointment of Damian is the first concrete step visible to our shareholders as we move from being an Australian biotech company to an international pharma company. We don't lack for ambition.

1. We are not satisfied, but when the entire sector goes down it is very hard to be one of the few that bucks the trend. This is not contained to Australia - the US and EU biotech markets are down even more than we are. Unfortunately in the stock market SP only roughly correlates with market potential at any one time.     2. You will just have to wait like everyone else :)     3. We have had a massive number of new shareholders come onto the register over the last 18 months, but we have also see

Top voted posts

Latest posts